Representing the Placement Agent in Rosetta Genomics Offerings

ZAG/S&W acted as counsel to Aegis Capital Corp. as sole placement agent in three offerings by Rosetta Genomics. Rosetta, which was on the verge of delisting from Nasdaq in early April 2012, was able to raise more than $10 million in three shelf takedowns, taking advantage of its existing shelf registration statement. Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are believed to play an important role in normal function and in various pathologies. Rosetta's integrative research platform led to the discovery of hundreds of biologically validated novel human microRNAs. Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools.

These three offerings, completed in aggressive timeframes, demonstrate ZAG/S&W's success in growing its underwriter practice.